Apomorphine ( DrugBank: Apomorphine )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
5	進行性核上性麻痺	1
6	パーキンソン病	60
7	大脳皮質基底核変性症	1

5. 進行性核上性麻痺

臨床試験数 : 89 / 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04786158 (ClinicalTrials.gov)	December 1, 2018	3/3/2021	Subcutaneous Apomorphinein the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degener ...	Subcutaneous Apomorphinein the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degener ...	Progressive Supranuclear Palsy;Corticobasal Degeneration	Drug: Apomorphine	Fondation Ophtalmologique Adolphe de Rothschild	NULL	Completed	18 Years	N/A	All	7		France

First Previous1Next Last

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 10 of 60 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04879134 (ClinicalTrials.gov)	February 28, 2022	4/5/2021	Apomorphine Effects on Pain in Parkinson's Disease	ApomorphineEffect on Pain in Parkinson's Disease: A Randomized, Double-blind Placebo Cross-over Stud ...	Parkinson Disease	Drug: Apomorphine Injectable Solution;Drug: Placebo	University of Calgary	Paladin Labs Inc.	Recruiting	18 Years	70 Years	All	40	Phase 2/Phase 3	Canada
2	NCT04887467 (ClinicalTrials.gov)	September 16, 2021	26/4/2021	Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcu ...	Pharmacokinetic Study of Continuous and Diurnal Subcutaneous ApomorphineInfusion in Patients With Pa ...	Parkinson Disease	Drug: Apomorphine	Rennes University Hospital	NULL	Recruiting	50 Years	70 Years	Male	20	Phase 4	France
3	EUCTR2021-000826-89-FR (EUCTR)	23/04/2021	25/03/2021	Etude pharmacocinétique de l’apomorphineen perfusion sous-cutanée continue diurne chez le patient pa ...	Etude pharmacocinétique de l’apomorphineen perfusion sous-cutanée continue diurne chez le patient pa ...	Parkinson's disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Trade Name: APOKINON Product Name: APOKINON Product Code: N04BC07	CHU Rennes	NULL	Authorised-recruitment may be ongoing or finished			Female: no Male: yes	20	Phase 4	France
4	EUCTR2019-003315-60-NL (EUCTR)	10/11/2020	08/10/2020	A study investigating the effect and safety of a new potential drug for Parkinson's disease patients ...	A phase 1/2 study investigating the pharmacokinetics, safety and efficacy of a highly concentrated b ...	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Trade Name: Apo-go Product Name: APO-go® INN or Proposed INN: Apomorphine Other descriptive name: APOMO ...	Criceto IKM B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	46	Phase 1;Phase 2	Netherlands
5	NCT04157933 (ClinicalTrials.gov)	October 16, 2019	1/11/2019	Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease	A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacoki ...	Parkinson's Disease	Drug: 009-A1;Drug: 009-A2;Drug: 009-A3;Drug: 009-A0;Drug: 009-B1 (active --> placebo) crossover;Drug ...	Alexza Pharmaceuticals, Inc.	NULL	Completed	30 Years	85 Years	All	35	Phase 1	Netherlands
6	NCT03693872 (ClinicalTrials.gov)	May 15, 2019	1/10/2018	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Relat ...	Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Relat ...	Parkinson Disease	Drug: Apomorphine;Drug: Dopaminergic Agonist + Apomorphine	Rennes University Hospital	NULL	Recruiting	18 Years	N/A	All	42	N/A	France
7	NCT03391882 (ClinicalTrials.gov)	December 19, 2018	2/1/2018	A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complic ...	An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 C ...	Motor OFF Episodes Associated With Parkinson's Disease	Drug: APL-130277;Drug: subcutaneous apomorphine	Sunovion	NULL	Completed	18 Years	N/A	All	113	Phase 3	Austria;France;Germany;Italy;Spain;United Kingdom
8	NCT03822364 (ClinicalTrials.gov)	November 26, 2018	18/12/2018	Staccato Apomorphine Single and Multi Dose PK	A Randomized Study of the Safety, Tolerability, and Pharmacokinetics of AZ-009 (Staccato Apomorphine ...	Parkinson Disease	Drug: 009-1;Drug: active comparator;Drug: 009-0;Drug: 009-2;Drug: 009-3;Drug: 009-4;Drug: 009-5	Alexza Pharmaceuticals, Inc.	NULL	Completed	18 Years	60 Years	All	56	Phase 1	Netherlands
9	EUCTR2016-003456-70-IT (EUCTR)	04/05/2018	02/02/2021	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphinein Parkinson¿s Dis ...	An Open-Label Randomized Crossover Trial, utilizing a Single-Blinded Rater to evaluate APL- 130277 c ...	Levodopa Responsive Patients with Parkinson¿s Disease Complicated by Motor Fluctuations (OFF episode ...	Product Name: Apomorphinehydrochloride Product Code: APL-130277 INN or Proposed INN: APOMORFINA CLORID ...	SUNOVION PHARMACEUTICALS INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy
10	EUCTR2016-003456-70-DE (EUCTR)	04/04/2018	03/04/2017	A clinical trial to compare APL-130277 sublingual film to Subcutaneous Apomorphinein Parkinson’s Dis ...	An Open-Label, Randomized, Crossover Trial utilizing a Single-Blinded Rater to evaluate APL-130277 c ...	Levodopa Responsive Patients with Parkinson’s Disease Complicated by Motor Fluctuations (OFF episode ...	Product Name: Apomorphinehydrochloride Product Code: APL-130277 INN or Proposed INN: Apomorphinehydroc ...	Sunovion Pharmaceuticals Inc.	NULL	Not Recruiting			Female: yes Male: yes	106	Phase 3	France;Spain;Austria;Germany;United Kingdom;Italy

First Previous1 2 3 4 5 6Next Last

先頭へ

7. 大脳皮質基底核変性症

臨床試験数 : 16 / 薬物数 : 28 - (DrugBank : 13) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 38

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04786158 (ClinicalTrials.gov)	December 1, 2018	3/3/2021	Subcutaneous Apomorphinein the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degener ...	Subcutaneous Apomorphinein the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degener ...	Progressive Supranuclear Palsy;Corticobasal Degeneration	Drug: Apomorphine	Fondation Ophtalmologique Adolphe de Rothschild	NULL	Completed	18 Years	N/A	All	7		France

First Previous1Next Last

先頭へ